Zanamivir, a transition-state analogue inhibitor of neuraminidase, was the result.In 1999, the product was approved for marketing in the US and Europe for treatment of influenza A and B. The FDA advisory committee had recommended by a vote 13 to 4 that it should not be approved, because it lacked efficacy and was no more effective than placebo when the patients were on other drugs such as paracetamol. But the FDA leadership overruled the committee and criticised its reviewer, biostatistician Michael Elashoff. The review of oseltamivir, which was also in approval process  at that time, was taken away from him, and reassigned to someone else. In 2006 zanamivir was approved in the US and Europe for prevention of influenza A and B.

References
External links
Drug Information: Zanamivir Inhalation MedlinePlus drug
Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line. It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year. References
External links
idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)